Publications by authors named "Xueru Ren"
Article Synopsis
- Bone or brain metastases occur in 20-40% of late-stage non-small-cell lung cancer (NSCLC) patients, leading to a poor median survival of 4-6 months, yet the distinctions in metastatic types at the single-cell level remain underexplored.
- A comprehensive analysis of 14 biopsy samples from treatment-naïve advanced NSCLC patients revealed significant differences in cancer-associated fibroblast (CAF) populations among the bone, brain, and intrapulmonary metastases.
- The study highlights the role of specific CAF subpopulations in promoting either bone or brain metastasis and suggests potential therapeutic targets by disrupting their interactions with tumor cells to inhibit metastasis.
Background: Durvalumab and atezolizumab have recently been approved in extensive small cell lung cancer (SCLC) with moderate median overall survival (OS) improvements. However, only limited data exist regarding the impact of immunotherapy in real-world SCLC patients. This study sought to assess the efficacy and safety of atezolizumab plus chemotherapy and durvalumab plus chemotherapy in the treatment of SCLC in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib is a targeted therapy that can effectively address T790M resistance mutations in non-small cell lung cancer (NSCLC), but the benefits of repeat rebiopsy in negative patients remain uncertain.
- A study of advanced NSCLC patients treated with first-generation EGFR-tyrosine kinase inhibitors showed that 66% developed T790M mutations, and the prevalence was 50.9% in those who underwent a rebiopsy after progressive disease.
- The median progression-free survival on osimertinib for T790M-positive patients was approximately 7 months for the first rebiopsy group and 6 months for the repeat rebiopsy group, indicating similar outcomes for both groups.